RAINBOW

Open-label trial with a long-term extension of RAY121 for the inhibition of the classical complement pathway in immunological diseases. Phase 1b

Condition studied : Bullous pemphigoid, Antiphospholipid syndrome, Autoimmune necrotising myopathy, Behçet’s disease, Dermatomyositis, Immune thrombocytopenic purpura
Treatment : Repeated subcutaneous administration of RAY121
Sponsor : CHUGAI
Principal Investigator : Pr. Christian Jorgensen
: NCT 06371417, EU CT 2023-507692-21-00
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site